BIA Sees Some Hope For Regulatory Alignment After Brexit
Transition Period Begins As UK Finally Leaves The EU
Executive Summary
Could the UK carry on playing a part in the European Medicines Agency from 2021? Much will depend on the complex negotiations on the future relationship that are expected to kick off in March.
You may also be interested in...
UK's MHRA Looks Beyond Brexit Transition Period
Now that the UK has left the EU, the UK’s medicines regulator says it will use the rest of this year to work out how best to ensure continuity of drug regulation after the Brexit transition period ends on 31 December.
UK MHRA Looks Beyond Brexit Transition
Now that the UK has left the EU, the UK’s medicines regulator says it will use the rest of this year to work out how best to ensure continuity of drug regulation after the Brexit transition period ends on 31 December.
EU Parliament Urges Post-Brexit Cooperation On Medicines
Life science companies will be pleased to hear that the European Parliament is pressing for close cooperation between the UK and the EU in the area of medicines regulation.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests:
